Alzchem Group Ag · XETR:ACT
Alzchem — Q1 2024 Earnings Presentation
34 slides from Alzchem's earnings presentation, Apr 30, 2024
Slide 1: Agile Science Pure Results
AGILE SCIENCE PURE RESULTS
Slide 2: Presenters and date: April 30, 2024
1 2024 ANDREAS NIEDERMAIER, CEO DR. GEORG WEICHSELBAUMER, CSO ANDREAS LOSLER, CFO April 30, 2024
Slide 3: Disclaimer
DISCLAIMER CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available info
Slide 4: Agenda — Analyst Presentation Q1 2024: Executive Summary
AGENDA — ANALYST PRESENTATION Q1 2024 Executive Summary
Slide 5: Highlights
© Alzchem Group AG / April 2024 HIGHLIGHTS Group sales stable at previous year’s level EBITDA increased materially by 32% to 24.9 m€ Free Cashflow strongly positive and significantly higher compared to prior year Business development continues at a high level Segment Specialty Chemicals highly contr
Slide 6: Verbund System — Fully Integrated Business Model
© Alzchem Group AG / April 2024 “VERBUND” SYSTEM — FULLY INTEGRATED BUSINESS MODEL AN Fine Chemicals and Pharma \4 Bioselect® Highly purified form of guanidine salts Hardeners and accelerators in ° BS DYHARD powder, paste and liquid form DCD FOR Versatile intermediate in various markets : METFORMIN
Slide 7: Investment Grant by EU Commission
INVESTMENT GRANT BY EU COMMISSION As a part of ASAP ("Act in Support of Ammunition Production") Alzchem Group AG awarded EUR 34.4 million investment grant by EU Commission * Part of ASAP funding instrument * Funding for the project has been provisionally approved by the EU Commission based on a Euro
Slide 8: Agenda — Business and Financial Details
AGENDA — ANALYST PRESENTATION Q1 2024 ll. Business and financial details
Slide 9: Basics & Intermediates
NITRALZ® CBerlka’ G CaD BASICS & INTERMEDIATES The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of
Slide 10: Basics & Intermediates Segment (in M€)
BASICS & INTERMEDIATES SEGMENT (in Me€) Challenging market environment SALES ANALYSIS 57.3 i 49.3 Qi Q2 Q3) 4 QI Q2 Q3 4 a 2022 2022 2022 2022 2023 2023 2023 2023 2024 | Qi Q2) Q3 Q4 QI Q2 Q3 Q4 Qt 1-3 1-3 2022 2022 2022 2022 2023 2023 2023 2023 2024 2023 2024
Slide 11: Specialty Chemicals
a oe ( CREAMINO Drmex' Bioselect® DYHARD ##% Creapure* SPECIALTY CHEMICALS The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.
Slide 12: Specialty Chemicals Segment (in M€)
SPECIALTY CHEMICALS SEGMENT (in M€) Specialty Chemicals drives growth and profitability course of Alzchem r+8.4% SALES ANALYSIS Qi Q2 Q3) 4 QI Q2 Q3 4 2022 2022 2022 2022 2023 2023 2023 2023 2024 ghly atfec iturn in the chemical industry and ntration on hig alli Qi Q2 93 4 Qt Q2 Q3 O QI 2022 2022 20
Slide 13: Other & Holding
The "Other & Holding" segment offers infrastructure and energy supply services a at our locations for the chemicals segments and for external customers. a, . | OTHER & HOLDING
Slide 14: Other & Holding Segment (in M€)
OTHER & HOLDING SEGMENT (in m€) Segment in line with Outlook Qi Q2 Q3 Q4- QI Q2- Q3_ 4 QI 2022 2022 2022 2022 2023 2023 2023 2023 2024 os COMMENTS * 2024 | * EBITDA at the 0.5 Qi Q2 Q3) 4 QI Q2 Q3 4 1-3 1-3 1-3 1-3 2022 2022 2022 2022 2023 2023 2023 2023 2024 2023 2024 2023 2024
Slide 15: Financial Overview
FINANCIAL OVERVIEW Sustained growth in profitability SALES (in M€) 150,4 Volume EBITDA (in M€) 18,9 ' Price EBITDA margin (in %) 12,6% Currency Earnings per Share (in €) 0,76 * Sales in Q 24 at previous ye level with different developments in our business segmen’ volume growth almost offset by price
Slide 16: Balance Sheet (in M€)
BALANCE SHEET (in mé) Working capital reduction and increase in equity ratio Other non-current assets Deferred taxes for pension provision Inventories Trade receivables Other current assets by 23.1 ME urrent and non-curt tly reduc hs Further in Equity Other non-current liabilities Pension provision
Slide 17: Cashflow (in M€)
CASHFLOW (in m€) Very stable financing situation paves the way for upcoming capex projects s, infrastructure and a new PV park in ity in first q 1 2024 at 6.9 ME
Slide 18: Outlook 2024
OUTLOOK 2024 (in me) Outlook confirmed: Growth in sales, EBITDA and EBITDA-margin expected COMMENTS * Development in Q1 2024 confirmed our outlook growth IW: ~ to approx. 570.0 ME gr growth to approx. 90.0 ME ts in Specialty chemicals continue to be the ver of Alzchem in sales and EBITDA reamino' it
Slide 19: Financial Calendar
FINANCIAL CALENDAR Upcoming dates* “subject to change APR 30 APR 30 MAY 7 MAY 13-15 JUN 6-7 AUG 1 SEP 23 SEP 25 NOV 7 NOV 13 NOV 25-26 2024 2024 2024 2024 2024 2024 2024 2024 2024 2024 2024 MS Berenberg Fireside Chat Kepler Cheuvreux Investor Group Call Annual General Meeting Friihjahrskonferenz War
Slide 20: Feedback
FEEDBACK We appreciate your feedback Were your expectations met? Are you missing any content? WE APPRECIATE YOUR FEEDBACK! QR-Code Teer ela]
Slide 21: Alzchem Group Investor Relations
alzchem group Investor Relations T +49 8621 86-2888 F +49 8621 86-502888 ir@alzchem.com
Slide 22: Agenda — Back-Up
AGENDA — ANALYST PRESENTATION Q1 2024 ll. Back-Up
Slide 23: Balance Sheet
© Alzchem Group AG / April 2024 BALANCE SHEET Alzchem Group MS ALZCHEM GROUP (IN TE) 31.12.2023 31.03.2024 Deviation -ALZCHEM GROUP (IN T€) 31.12.2023 31.03.2024 Deviation Intangible assets 2664 2751 87 28% Share capital 101.763 101.763 Tangible assets W281 16.198 -483 0.3% RETAINED EARNINGS (+) / L
Slide 24: Pension Accounting (IFRS)
PENSION ACCOUNTING (IFRS) Alzchem Group (M€) IN FINANCIAL PENSION SERVICE NET INTEREST PENSION PENSION PENSION STATEMENT PROVISION costs costs PAYMENTS REMEASURE- PROVISION 31.12.2023 A MENTS 31.03.2024 eiNANciA RESULT BALANCE SHEET P&L CASHFLOW, * Interest rates increased from 3.2% to 3. ind led to
Slide 25: Income Statement
© Alzchem Group AG / April 2024 INCOME STATEMENT AN Alzchem Group Gy ALZCHEM GROUP (INTE) ak a. Pon oe sos on on on Deviation (Qt) Revenue 150432176599 120.824 142.794 180.064 “368 0% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 916 9.105 17 13972 -6521 7436 -812
Slide 26: Income Statement
INCOME STATEMENT Alzchem Group ALZCHEM GROUP (IN TE) sos oh Devietion (Q0Q) Revenue 150.432 150.064 ~368 ~0.2% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 216 ~6521 7436 -812,0% Other income 3.558 “2016 -36,2% Raw materials and consumables used 53.237 2.92 -30,1
Slide 27: Cashflow Statement
CASHFLOW STATEMENT Alzchem Group 5 a a CASHFLOW (IN ME) ooo ooo “Consolidated earrings before taxes 10.765 728 Depreciation an fixed and intangible assets 6320 e534 Decrease in pension provisions 564 Loss (+) / Profit (- rom the sale of non-currant assets - Other non-cash income (-) and expenses (+)
Slide 28: Segment Overview by Quarter
SEGMENT OVERVIEW BY QUARTER iN Alzchem Group v SALES 4 viati SALES Q2 Q3 Q Deviation PY (Q1) Te Te Te Te % Basics & Intermediates 8.037 -14% Specialty Chemicals 7:78 8% Other and Holding 491 Alzchem Group, 139.193 133.200 150.064 EBITDA EBITDA Qa Q3 22 Q3_—QA_esiation PY(QH Te Te Te Te Te Te % Basic
Slide 29: Alzchem Group Locations
ALZCHEM GROUP LOCATIONS Production sites and sales companies COVENTRY (UK) s 2 oy g s 6 E ATLANTA (USA) ® SALES COMPANY
Slide 30: Implementing Operating Targets 2024
© Alzchem Group AG / April 2024 IMPLEMENTING OPERATING TARGETS 2024 Focus on the key growth drivers and sustainability IMPROVEMENT * Pass on raw material price increases to the market * Flexibilization of production and processes * Volume growth & full capacity utilization GROWTH * Increase the avai
Slide 31: Verbund — Fully Integrated Business Model
© Alzchem Group AG / April 2024 “VERBUND” — FULLY INTEGRATED BUSINESS MODEL AN Benefits of the “Verbund” system approach tay O Segment Specialty Chemicals BENEFITS OF “VERBUND” O Segment Basics & Inter- * Full control of product quality and specifications mediates * Lower costs * Higher financial pr
Slide 32: Our Products and Markets
OUR PRODUCTS AND MARKETS i, iN Successful with proven and new products in various industries (ay MAIN PRODUCTS DESCRIPTION END-MARKETS CREAMINO’ = Anutritional additive for poultry and pigs Feed additive Creapure’ Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nut
Slide 33: Our Products and Markets
© Alzchem Group AG / April2024 OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries \N Pharmaceutical MAIN PRODUCTS DESCRIPTION END-MARKETS @ Calcium carbide-based mixtures for hot metal desulphurization Steel industry ny Guanidine Salts Fuel for airbags, key produc
Slide 34: Key Share Data
© Alzchem Group AG / April 2024 KEY SHARE DATA Share Details as of April 26, 2024 SHARES OUTSTANDING LAST CLOSING PRICE MARKET CAPITALIZATION TICKER WKN ISIN LISTING DESIGNATED SPONSOR 10,176,335 EUR 45.80 EUR 466m ACT A2YNT3 DEOOOA2YNT30 Frankfurt Stock Exchange — Prime Standard Baader Bank AG ODDO